×

Cost of failure high in biotech space: Pro

7:16 AM ET Mon, 28 Dec 2015

Barbara Ryan, Clermont Partners, shares her thoughts on innovation in the biotech space and the high cost of developing new drugs. And Scott Sperling, THL Partners, weighs in.